Stiefel launches new acne drug

Fabior was approved last year

NEW YORK — Stiefel has launched a new drug for treating acne, the company said Tuesday.

Stiefel, which is a subsidiary of British drug maker GlaxoSmithKline, announced the launch of Fabior (tazarotene) foam, which it called the only retinoid in a topical foam formulation for acne vulgaris in patients aged 12 and older.

The drug originally received Food and Drug Administration approval in May 2012.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

Login or Register to post a comment.